Emerging Infectious Disease ISSN: 1080-6059

Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany

Johannes Elias

, Leo M. Schouls, Ingrid van de Pol, Wendy C. Keijzers, Diana R. Martin, Anne Glennie, Philipp Oster, Matthias Frosch, Ulrich Vogel¹, and Arie van der Ende¹

Author affiliations: University of Wuerzburg, Wuerzburg, Germany (J. Elias, M. Frosch, U. Vogel); National Institute for Public Health and Environment (RIVN), Bilthoven, the Netherlands (L.M. Schouls, I. van de Pol); Academic Medical Center, Amsterdam, the Netherlands (W.C. Keijzers, A. van der Ende); Institute of Environmental Science and Research, Porirua, New Zealand (D.R. Martin, A. Glennie); Novartis Vaccines, Siena, Italy (P. Oster)

Main Article

Figure 4

Kernel density plots of age distribution of MT19/ST42 case-patients compared with the rest of the ST41/44 complex. The vertical gray line indicates 10 years.

Figure 4. Kernel density plots of age distribution of MT19/ST42 case-patients compared with the rest of the ST41/44 complex. The vertical gray line indicates 10 years.

Main Article

¹These authors contributed equally to this article.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.